Initial Experience of 68Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy

European Urology

Volumn 69, Issue 3, 2016, Pages 393-396

  Budäus, Lars ^a   Leyh Bannurah, Sami Ramzi ^a   Salomon, Georg ^a   Michl, Uwe ^a   Heinzer, Hans ^a   Huland, Hartwig ^a   Graefen, Markus ^a   Steuber, Thomas ^a   Rosenbaum, Clemens ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Imaging; Lymph node metastasis; Positron emission tomography; Prostate cancer; Prostate specific membrane antigen

Indexed keywords

PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN GA 68; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; EDETIC ACID; GLU-NH-CO-NH-LYS-(AHX)-((68)GA(HBED-CC)); KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; OLIGOPEPTIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; BIOCHEMICAL RECURRENCE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PERSONAL EXPERIENCE; PET-CT SCANNER; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; AGED; ANALOGS AND DERIVATIVES; DIAGNOSTIC IMAGING; LYMPH NODE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE CARE; PROCEDURES; PROSTATIC NEOPLASMS; RISK FACTOR; TREATMENT OUTCOME; X-RAY COMPUTED TOMOGRAPHY;

ADULT; AGED; EDETIC ACID; HUMANS; KALLIKREINS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; OLIGOPEPTIDES; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PREOPERATIVE CARE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; RISK FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84932174405     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2015.06.010     Document Type: Article

References (13)

1. A. Briganti, M.L. Blute, J.H. Eastham, and et al. Pelvic lymph node dissection in prostate cancer Eur Urol 55 2009 1251 1265
2. A. Afshar-Oromieh, C.M. Zechmann, A. Malcher, and et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer Eur J Nucl Med Mol Imaging 41 2014 11 20
3. S.D. Sweat, A. Pacelli, G.P. Murphy, and D.G. Bostwick Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases Urology 52 1998 637 640
4. A. Briganti, F.K. Chun, A. Salonia, and et al. Validation of a nomogram predicting the probability of lymph node invasion among patients undergoing radical prostatectomy and an extended pelvic lymphadenectomy Eur Urol 49 2006 1019 1026 discussion 1026-7
5. L. Evangelista, A. Guttilla, F. Zattoni, P.C. Muzzio, and F. Zattoni Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate-to high-risk prostate cancer: a systematic literature review and meta-analysis Eur Urol 63 2013 1040 1048
6. T. Steuber, T. Schlomm, H. Heinzer, and et al. [F(18)]-fluoroethylcholine combined in-line PET-CT scan for detection of lymph-node metastasis in high risk prostate cancer patients prior to radical prostatectomy: preliminary results from a prospective histology-based study Eur J Cancer 46 2010 449 455
7. R. Schiavina, V. Scattoni, P. Castellucci, and et al. 11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms Eur Urol 54 2008 392 401
8. A. Afshar-Oromieh, E. Avtzi, F.L. Giesel, and et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer Eur J Nucl Med Mol Imaging 42 2015 197 209
9. L. Nalin, R.K. Selvaraju, I. Velikyan, and et al. Positron emission tomography imaging of the glucagon-like peptide-1 receptor in healthy and streptozotocin-induced diabetic pigs Eur J Nucl Med Mol Imaging 41 2014 1800 1810
10. C. Pegard, C. Gallazzini-Crepin, J. Giai, and et al. Study of inter- and intra-observer reproducibility in the interpretation of [(18)F]choline PET/CT examinations in patients suffering from biochemically recurrent prostate cancer following curative treatment EJNMMI Res 4 2014 25
11. F.D. Birkhauser, U.E. Studer, J.M. Froehlich, and et al. Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging facilitates detection of metastases in normal-sized pelvic lymph nodes of patients with bladder and prostate cancer Eur Urol 64 2013 953 960
12. E. Kahkonen, I. Jambor, J. Kemppainen, and et al. In vivo imaging of prostate cancer using [68Ga]-labeled bombesin analog BAY86-7548 Clin Cancer Res 19 2013 5434 5443
13. A. Afshar-Oromieh, U. Haberkorn, H.P. Schlemmer, and et al. Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience Eur J Nucl Med Mol Imaging 41 2014 887 897